>
Switch to:

Biohaven Pharmaceutical Holding Co Cash-to-Debt

: 1.34 (As of Jun. 2021)
View and export this data going back to 2017. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biohaven Pharmaceutical Holding Co's cash to debt ratio for the quarter that ended in Jun. 2021 was 1.34.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Biohaven Pharmaceutical Holding Co could pay off its debt using the cash in hand for the quarter that ended in Jun. 2021.

The historical rank and industry rank for Biohaven Pharmaceutical Holding Co's Cash-to-Debt or its related term are showing as below:

NYSE:BHVN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.33   Med: 3964.2   Max: No Debt
Current: 1.34

1.33
No Debt

During the past 6 years, Biohaven Pharmaceutical Holding Co's highest Cash to Debt Ratio was No Debt. The lowest was 1.33. And the median was 3964.20.

NYSE:BHVN's Cash-to-Debt is ranked lower than
98% of the 319 Companies
in the Biotechnology industry.

( Industry Median: 10.28 vs. NYSE:BHVN: 1.34 )

Biohaven Pharmaceutical Holding Co Cash-to-Debt Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cash-to-Debt
Premium Member Only 4.90 363.17 No Debt No Debt 1.33

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt 2.07 1.33 2.09 1.34

Competitive Comparison

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven Pharmaceutical Holding Co Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's Cash-to-Debt falls into.



Biohaven Pharmaceutical Holding Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biohaven Pharmaceutical Holding Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2020 is calculated as:

Biohaven Pharmaceutical Holding Co's Cash to Debt Ratio for the quarter that ended in Jun. 2021 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Biohaven Pharmaceutical Holding Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co Business Description

Biohaven Pharmaceutical Holding Co logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Bailey Gregory director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Gentile Kimberly officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Childs John W director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Berman Robert officer: Special Projects & Med Ovrsght C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Doogan Declan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Stock Elyse officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
Engelhart James officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Tilton John officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Hugin Robert J director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Heffernan Michael Thomas director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Gregory Julia P director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Aguiar Eric director 888 7TH AVENUE 12TH FLOOR NEW YORK NY 10106
Coric Vlad director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC. 125 SPRING STREET LEXINGTON MA 02421
Conway Charles officer: Chief Scientific Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510

Biohaven Pharmaceutical Holding Co Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)